🇺🇸 FDA
Patent

US 12378558

RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use

granted A61PA61P13/12

Quick answer

US patent 12378558 (RNAi agents for inhibiting expression of complement factor B (CFB), pharmaceutical compositions thereof, and methods of use) held by Arrowhead Pharmaceuticals, Inc. expires Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Arrowhead Pharmaceuticals, Inc.
Grant date
Tue Aug 05 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 31 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61P, A61P13/12